8.67
+0.14(+1.64%)
Currency In USD
| Previous Close | 8.53 |
| Open | 8.5 |
| Day High | 8.76 |
| Day Low | 8.2 |
| 52-Week High | 22.9 |
| 52-Week Low | 6.42 |
| Volume | 39,100 |
| Average Volume | 47,886 |
| Market Cap | 17.99M |
| PE | -0.99 |
| EPS | -8.72 |
| Moving Average 50 Days | 9.82 |
| Moving Average 200 Days | 12.72 |
| Change | 0.14 |
If you invested $1000 in Cadrenal Therapeutics, Inc. Common Stock (CVKD) since IPO date, it would be worth $140.29 as of January 14, 2026 at a share price of $8.67. Whereas If you bought $1000 worth of Cadrenal Therapeutics, Inc. Common Stock (CVKD) shares 2 years ago, it would be worth $737.24 as of January 14, 2026 at a share price of $8.67.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibitor
GlobeNewswire Inc.
Jan 12, 2026 1:00 PM GMT
Company to also participate in Fireside Chat at Lytham Partners 2026 Investor Healthcare Summit on Thursday, January 15, 2026SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company de
Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026
GlobeNewswire Inc.
Dec 17, 2025 2:00 PM GMT
PONTE VEDRA, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of current anticoagulation therapy, today announced that
Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)
GlobeNewswire Inc.
Dec 11, 2025 1:05 PM GMT
Novel first-in-class therapeutic targeting a key immune signaling pathway and the underlying cause of HITIt is the first and only potent, highly selective inhibitor of human 12-LOX in clinical testing, distinguishing it from related compounds.Orphan